Brought to you by 
CoAxia gets $21.5mm through its Series D round
24 Sep 2020
Executive Summary
First-time backer Sofinnova Partners has led CoAxia's (ischemia devices) $21.5mm oversubscribed Series D venture round and will contribute a board member. All prior major investors--Affinity Capital Management, Baird Venture Partners, Canaan Venture Partners, Johnson & Johnson Development Corp., and Prism Ventureworks--participated. CoAxia will use the funds to finish its pivotal trial of NeuroFlo for acute ischemic stroke and to investigate the product in combination with other devices and drugs.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com